Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease

Basit Öğe Kaydı
dc.contributor.authorGüney, İbrahim
dc.contributor.authorSelçuk, N. Yılmaz
dc.contributor.authorAltıntepe, Lütfullah
dc.contributor.authorAtalay, Hüseyin
dc.contributor.authorBaşarali, M. Kemal
dc.contributor.authorBüyükbaş, Sadık
dc.date.accessioned2020-03-26T17:37:52Z
dc.date.available2020-03-26T17:37:52Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAims. Proteinuria and transforming growth factor beta (TGF-beta) are parameters that can lead to glomerulosclerosis and tubulointerstitial fibrosis. All components of the renin-angiotensin-aldosterone system (RAAS) activate the TGF-beta. Aldosterone may not be inhibited with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) due to aldosterone escape. We aimed to evaluate the effect of spironolactone on parameters leading to fibrosis. Methods. This prospective study included 30 non-diabetic chronic kidney disease (CKD) patients treated with ACEIs and/or ARBs. The patients were divided into two groups that are similar in terms of demographic parameters. 25 mg of spironolactone was added to group 1 (n = 15) for six months, though it was not administered to group 2 (n = 15). Creatinine (U-Cr), protein (U-Prot), and TGF-beta 1 (U-TGF-beta 1) were measured in spot urine sample in the beginning of study and six months later. Results. Twenty-four patients completed the study. There were no significant changes in mean blood pressure, glomerular filtration rate, creatinine, albumin, and plasma aldosterone concentrations during the observation period in either group. U-Prot/U-Cr (mg/mg Cr) was reduced from 2.43 +/- 4.85 at baseline to 1.66 +/- 3.51 at sixth month (p = 0.003) in group 1. In addition, U-TGF-beta 1/U-Cr (ng/mg Cr) was also reduced from 22.50 +/- 6.65 at baseline to 17.78 +/- 10.94 at sixth month (p = 0.041) in the same group. U-TGF-beta 1/U-Cr and U-Prot/U-Cr ratios after the sixth month were not found significant compared with baseline values in group 2. Conclusion. Spironolactone reduced both proteinuria and urinary TGF-beta 1 excretion in CKD patients. We consider that spironolactone would be beneficial to prevent progression of renal fibrosis in CKD.en_US
dc.description.sponsorshipAli Raif Drug Industry A.C.en_US
dc.description.sponsorshipThis study was supported by Ali Raif Drug Industry A.C. for providing TGF-beta 1 and aldosterone kits.en_US
dc.identifier.doi10.3109/08860220903150312en_US
dc.identifier.endpage784en_US
dc.identifier.issn0886-022Xen_US
dc.identifier.issn1525-6049en_US
dc.identifier.issue9en_US
dc.identifier.pmid19925284en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage779en_US
dc.identifier.urihttps://dx.doi.org/10.3109/08860220903150312
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23284
dc.identifier.volume31en_US
dc.identifier.wosWOS:000273987900002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofRENAL FAILUREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectTGF-beta 1en_US
dc.subjectchronic kidney diseaseen_US
dc.subjectspironolactoneen_US
dc.subjectproteinuriaen_US
dc.titleAntifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu